Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Antibacterial
    (5)
  • Apoptosis
    (15)
  • Autophagy
    (41)
  • Caspase
    (5)
  • ERK
    (6)
  • JNK
    (7)
  • MAPK
    (5)
  • NF-κB
    (14)
  • p38 MAPK
    (81)
  • Others
    (46)
Filter
Search Result
Results for "p38 MAPK" in TargetMol Product Catalog
  • Inhibitor Products
    154
    TargetMol | Activity
  • Natural Products
    47
    TargetMol | inventory
  • Recombinant Protein
    14
    TargetMol | natural
  • Peptides Products
    3
    TargetMol | composition
p38 MAPK Inhibitor
T36010219138-24-6In house
p38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM). It inhibits senescence induced by the oncogene RAS.
  • $147
In Stock
Size
QTY
TargetMol | Inhibitor Sale
p38 MAPK-IN-2
T11241635725-16-5
p38 MAPK-IN-2 is an inhibitor of p38 kinase.
  • $1,520
6-8 weeks
Size
QTY
p38 MAPK-IN-3
T61803
p38 MAPK-IN-3 (Compound 2c) is a potent inhibitor of p38α MAPK, displaying antitumor properties by promoting apoptosis and increasing reactive oxygen species (ROS) production [1].
  • $1,520
10-14 weeks
Size
QTY
p38 MAP Kinase Inhibitor IV
T360111638-41-1
p38 MAPK inhibitor IV is an ATP-competitive inhibitor of p38 MAP kinases with IC50 values of 0.13, 0.55, 5.47, and 8.63 μM for p38α, p38β, p38x, and p38δ, respectively, in vitro.[1] It also inhibits LPS-induced TNF-α and IL-1β cytokine production (IC50s = 22 and 44 nM, respectively) in human peripheral blood mononuclear cells.
  • $155
35 days
Size
QTY
p38 MAPK-IN-1
T164241006378-90-0
p38 MAPK-IN-1 displays sustained levels, low clearance, and good bioavailability. p38 MAPK-IN-1 is a novel effective and selective inhibitor of p38 MAPK (IC50: 68 nM).
  • $198
8-10 weeks
Size
QTY
p38-α MAPK-IN-1
T12347443913-15-3
p38-α MAPK-IN-1 is a MAPK14 (p38-α) inhibitor(IC50 of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay).
  • $98
In Stock
Size
QTY
p38-α MAPK-IN-5
T706381443242-46-3
P38-α MAPK-IN-5 is a potent inhibitor of p38α, demonstrating inhibitory concentrations (IC50) of 0.1 nM for p38α, 0.2 nM for p38β, 944 nM for p38γ, and 4100 nM for p38δ. It exhibits anti-inflammatory properties and holds potential for research in asthma and chronic obstructive pulmonary disease (COPD).
  • $2,420
10-14 weeks
Size
QTY
p38-α MAPK-IN-4
T610912396754-57-5
p38-α MAPK-IN-4 (Compound 69) is a selective inhibitor of p38α MAPK, demonstrating potent inhibition with an IC50 of 1.5 μM. It effectively and swiftly mitigates the onset of mechanical allodynia (MA) in vivo [1].
  • $1,520
6-8 weeks
Size
QTY
(S)-p38 MAPK Inhibitor III
T35420581098-48-8
(S)-p38 MAPK inhibitor III is a methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 μM in vitro). It is cell-permeable, potently blocking the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 μM, respectively).
  • $170
35 days
Size
QTY
Butein
T6427487-52-5
Butein (2’,3,4,4’-tetrahydroxy Chalcone), a plant polyphenol, is isolated from Rhus verniciflua. It can inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, and also can inhibit EGFR.
  • $36
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
LXH254
T118981800398-38-2
LXH254 is a potent C-Raf and B-Raf inhibitor.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Hot
VX-702
T2513745833-23-2In house
VX-702 is a highly specific p38α MAPK inhibitor, 14-fold higher selectivity for the p38α than p38β. VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA).
  • $50
In Stock
Size
QTY
SB 202190
T2301152121-30-7
SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38α and p38β2 (IC50=50/100 nM) selectively and cell-permeably. SB 202190 has antitumor activity and also induces the differentiation of human embryonic stem cells into cardiomyocytes.
  • $35
In Stock
Size
QTY
TargetMol | Citations Cited
Dihydrocaffeic acid
T05391078-61-1
Dihydrocaffeic acid is a metabolite of chlorogenic acid, a well-known antioxidant component with antioxidant, anti-Alzheimer's disease, neuroprotective, arousal and lipid-lowering effects.
  • $50
In Stock
Size
QTY
UR13870
T29071755753-89-0In house
UR-13870 (Org 48762-0) is an orally active and selective inhibitor of p38 mitogen-activated protein kinase (MAPK), which prevents bone damage in collagen-induced arthritis in mice.
  • $293
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Iroxanadine
T27627203805-20-3In house
Iroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.CAS 번호13480-84-5
  • $146
In Stock
Size
QTY
Apelin-12 acetate
T39823L
Apelin-12 acetate possesses a high affinity to orphan receptor APJ receptor. Apelin-12 acetate inhibits the JNK and p38 MAPK signaling pathway of the apoptosis-related MAPKs family, thus offering protection to neurons.
  • $228
In Stock
Size
QTY
DIPQUO hydrochloride
T11048L In house
DIPQUO hydrochloride is an activator of the bone marker alkaline phosphatase (ALP), with an EC50 of 6.27 μM in C2C12 cells. DIPQUO hydrochloride promotes mouse and human osteoblast differentiation via activation of p38 MAPK-β.
  • $107
In Stock
Size
QTY
TargetMol | Inhibitor Sale
SSK1
T374502629250-69-5In house
SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells.
  • $215 TargetMol
In Stock
Size
QTY
TargetMol | Inhibitor Sale
JNJ-49095397
T729181220626-82-3In house
JNJ-49095397 (RV568) is a selective p38 MAPK-α and p38 MAPK--γ kinase inhibitor with anti-inflammatory activity and potential antiviral activity for chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory syncytial virus infection.
  • $88
In Stock
Size
QTY
Muramyl dipeptide
T1615953678-77-6In house
Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. Muramyl dipeptide indirectly decreases osteoclast differentiation through a decreased RANKL/OPG ratio. Muramyl dipeptide directly increases osteoblast differentiation by up-regulating Runx2 gene expression through MAPK pathways. Muramyl dipeptide is an inducer of bone formation through the induction of Runx2 .
  • Inquiry Price
5 days
Size
QTY
TargetMol | Inhibitor Sale
AL 8697
T102771057394-06-5In house
AL 8697 is a selective p38α MAPK inhibitor (IC50 = 6 nM) with 14-fold selectivity over p38β (IC50 = 82 nM) and 300-fold selectivity over a panel of 91 kinases. AL 8697 has anti-inflammatory activity.
  • $64
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Talmapimod
T12871309913-83-5In house
Talmapimod (SCIO-469) is an selective, orally active, and ATP-competitive p38α inhibitor with IC50 of 9 nM and 90 nM for p38α and p38β, respectively. Talmapimod exhibits at least 2000-fold selectivity over a panel of 20 kinases, including other MAPKs.
  • $48
In Stock
Size
QTY
SR-318
T129972413286-32-3In house
SR-318 is a potent and highly selective inhibitor of p38 MAPK(IC50s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively), has anti-cancer and anti-inflammatory activity.
  • $38
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Doramapimod
T6277285983-48-4
Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70.
  • $31
In Stock
Size
QTY
TargetMol | Citations Cited
Caffeic Acid Phenethyl Ester
T6429104594-70-9
Caffeic Acid Phenethyl Ester (Phenylethyl Caffeate) (CAPE) inhibits the activation of nuclear transcription factor NF-kappa B and may suppress p70S6K and Akt-driven signaling pathways, with antineoplastic, cytoprotective and immunomodulating activities. CAPE is the phenethyl alcohol ester of caffeic acid and a bioactive component of honeybee hive propolis. In addition, CAPE inhibits PDGF-induced proliferation of vascular smooth muscle cells through the activation of p38 mitogen-activated protein kinase (MAPK) and hypoxia-inducible factor (HIF)-1alpha and subsequent induction of heme oxygenase-1 (HO-1).
  • $33
In Stock
Size
QTY
TargetMol | Citations Cited
Ralimetinib dimesylate
T6047862507-23-1
Ralimetinib dimesylate (LY2228820 dimesylate) is the dimesylate salt form of LY2228820, a tri-substituted imidazole derivative and orally available, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential anti-inflammatory and antineoplastic activities.
  • $35
In Stock
Size
QTY
TargetMol | Citations Cited
Calycosin
T392320575-57-9
Calycosin (Cyclosin) acts as a selective estrogen receptor modulator. Calycosin induces apoptosis in human ovarian cancer SKOV3 cells by activating caspases and Bcl-2 family proteins. Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways. Calycosin has antineoplastic effects against osteosarcoma through inducing apoptosis showing in vitro and in vivo investigations. Calycosin was shown to induce angiogenesis in human umbilical vein endothelial cell cultures (HUVEC) in vitro. Calycosin may be an effective skin-lightening agent that regulates the expression of melanogenic enzymes. Calycosin exhibited tyrosinase inhibitory activity with an IC(50) value of 38.4 microM.
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
Lawsone methyl ether
T30082348-82-5
Lawsone methyl ether (2-Methoxy-1,4-naphthoquinone) induced apoptosis of A549 cells independent of cell cycle arrest, and is mediated by the JNK and p38 MAPK signaling pathways. Further analysis demonstrated that these signaling pathways were stimulated by oxidative DNA damage caused by increased ROS generation in MNQ-treated A549 cells.
  • $37
In Stock
Size
QTY
TargetMol | Citations Cited
Adezmapimod
T1764152121-47-6
Adezmapimod (SB 203580) is a p38 MAPK inhibitor (IC50=0.3-0.5 μM) that is selective and ATP-competitive. Adezmapimod possesses autophagy and mitochondrial autophagy activating activity. Adezmapimod displays more than 100-fold higher selectivity than PKB, LCK, and GSK-3β.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
Neochlorogenic acid
T6S1538906-33-2
Neochlorogenic acid (trans-5-O-Caffeoylquinic acid) is an antioxidant compound used in the treatment of oxidative stress and related afflictions.
  • $140
In Stock
Size
QTY
TargetMol | Citations Cited
Losmapimod
T2277585543-15-3
Losmapimod (GSK-AHAB) (GW856553X; SB856553; GSK-AHAB) is a specific, potent, and orally active p38 MAPK inhibitor (pKi: 8.1/7.6 for p38α/β).
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
BI-3406
T129792230836-55-0
BI-3406 is an orally active, highly potent and selective between KRAS and Son of Sevenless 1 (SOS1) interaction inhibitor(IC50 : 6 nM),with anticancer activity.
  • $67
In Stock
Size
QTY
TargetMol | Citations Cited
(E)-SIS3
T3636521984-48-5
(E)-SIS3 (SIS3), a selective Smad3 inhibitor, can attenuate TGF-β1-dependent Smad3 phosphorylation and DNA binding. It has no effect on p38 MAPK, Smad2, ERK or PI3K signaling. It also inhibits TGF-β1-induced myofibroblast differentiation of dermal fibroblasts and inhibits TGF-β2-induced endothelial cell differentiation in iPSCs.
  • $36
In Stock
Size
QTY
TargetMol | Citations Cited
Afatinib
T21312850140-72-6
Afatinib (BIBW 2992) is an irreversible inhibitor of EGFR family (EGFR-wt, EGFR-L858R, EGFR-L858R/T790M and HER2 with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM , respectively).
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
Panaxydol
TN203972800-72-7
Panaxydol has anti-cancer activity, can inhibit the growth and apoptosis of cancer cells, the signaling mechanisms involve a [Ca(2+)](i) increase, JNK and p38 MAPK activation, cAMP, MAP kinase and ROS generation through NADPH oxidase and mitochondria.
  • $220
Backorder
Size
QTY
TargetMol | Inhibitor Sale
Neoechinulin A
TN463551551-29-2
Neoechinulin A has anti-inflammatory effect against LPS-stimulated RAW264.7 macrophages through inhibition of the NF-κB and p38 MAPK pathways, it may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regu
  • $620
Backorder
Size
QTY
TargetMol | Inhibitor Sale
(±)14(15)-EET
T35463197508-62-6
(±)14(15)-EET is a metabolite of arachidonic acid that is formed via epoxidation of arachidonic acid by cytochrome P450.[1],[2] It prevents increases in leukotriene B4, ICAM-1, and chemokine (C-C motif) ligand 1 (CCL2) induced by oxidized LDL in primary rat pulmonary artery endothelial cells (RPAECs) when used at a concentration of 1 μM.[3] (±)14(15)-EET induces dilation of preconstricted isolated canine coronary arterioles (EC50 = 0.2 pM).[4] It reduces myocardial infarct size as a percentage of the area at risk in a canine model of ischemia-reperfusion injury induced by left anterior descending coronary artery (LAD) occlusion when administered at a dose of 0.128 mg/kg prior to occlusion or reperfusion.[5] Reference:[1]. Chacos, N., Falck, J.R., Wixtrom, C., et al. Novel epoxides formed during the liver cytochrome P-450 oxidation of arachidonic acid. Biochem. Biophys. Res. Commun. 104(3), 916-922 (1982).[2]. Oliw, E.H., Guengerich, F.P., and Oates, J.A. Oxygenation of arachidonic acid by hepatic monooxygenases. Isolation and metabolism of four epoxide intermediates. J. Biol. Chem. 257(7), 3771-3781 (1982).[3]. Jiang, J.-X., Zhang, S.-J., Xiong, Y.-K., et al. EETs attenuate ox-LDL-induced LTB4 production and activity by inhibiting p38 MAPK phosphorylation and 5-LO/BLT1 receptor expression in rat pulmonary arterial endothelial cells. PLoS One 10(6), e0128278 (2015).[4]. Oltman, C.L., Weintraub, N.L., VanRollins, M., et al. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ. Res. 83(9), 932-939 (1998).[5]. Nithipatikom, K., Moore, J.M., Isbell, M.A., et al. Epoxyeicosatrienoic acids in cardioprotection: Ischemic versus reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 291(2), H537-H542 (2006).
  • $535
35 days
Size
QTY
TargetMol | Inhibitor Sale
Asatone
T1038338451-63-7
Asatone, an active component isolated from Radix et Rhizoma Asari, has an anti-inflammatory effect via activation of NF-κB and downregulation of p-MAPK (ERK, JNK, and p38) pathways.
  • $90
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Olodanrigan
T44311316755-16-4
Olodanrigan (EMA401), a highly selective AT2R antagonist, inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons. EMA401 blocks p38, p42/p44 mitogen-activated protein kinase (MAPK) activation, neurite outgrowth in adult rat DRG neurons, and sensitization of adult rat and human DRG neurons induced by AngII. It inhibits capsaicin responses in cultured hDRG neurons.
  • $42
In Stock
Size
QTY
TargetMol | Inhibitor Sale
OVA-E1 peptide TFA
T386651262750-80-0
OVA-E1 peptide TFA activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.
  • $154
Backorder
Size
QTY
TargetMol | Inhibitor Sale
SD-169
T76611670-87-7
SD-169 (SD 169) is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Trichosanatine
TN5174169626-16-8
Trichosanatine and squamosamide, as potential candidates as lead compounds for further study in drug development process with the PP2A- α protein. Trichosanatine can alleviate oxidized low-density lipoprotein induced endothelial cells injury via inhibiting the LOX-1/p38 MAPK pathway.
  • $950
Backorder
Size
QTY
TargetMol | Inhibitor Sale
Tpl2 Kinase Inhibitor (hydrochloride)
T35536
Tpl2 kinase inhibitor is an inhibitor of tumor progression locus 2 (Tpl2; IC50= 0.05 μM).1It is selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC50s = >40, 180, >400, 110, and >400 μM, respectively). Tpl2 kinase inhibitor inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC50s = 0.7 and 8.5 μM, respectively). It enhances differentiation induced by calcitriol in HL-60 and U937 leukemia cells when used at a concentration of 5 μM.2Tpl2 kinase inhibitor (5 μM) inhibits the proliferation of KG-1a leukemia cells.3 1.Garvin, L.K., Green, N., Hu, Y., et al.Inhibition of Tpl2 kinase and TNF-α production with 1,7-naphthyridine-3-carbonitriles: Synthesis and structure-activity relationshipsBioor. Med. Chem. Lett.15(23)5288-5292(2005) 2.Wang, X., and Studzinski, G.P.Expression of MAP3 kinase COT1 is up-regulated by 1,25-dihydroxyvitamin D3 in parallel with activated c-jun during differentiation of human myeloid leukemia cellsJ. Steroid. Biochem. Mol. Biol.121(1-2)395-398(2010) 3.Wang, X., Gocek, E., Novik, V., et al.Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D3Cell Cycle9(22)4542-4551(2010)
  • $143
35 days
Size
QTY
TargetMol | Inhibitor Sale
SM-7368
T22115380623-76-7
The NF-κB Activation Inhibitor III, controls the biological activity of NF-κB. It is primarily used for Inflammation/Immunology applications.
  • $38
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CMPD1
T1498841179-33-3
CMPD1 is a non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor(apparent Ki (Kiapp): 330 nM).
  • $44
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Grasshopper ketone
TN538741703-38-2
Grasshopper ketone, isolated from the brown alga Sargassum, is a potent inhibitor of LPS-induced NO production in RAW 264.7 cells and induces anti-inflammatory effects by inhibiting MAPK (ERK, JNK and p38) and NF-κB p65 phosphorylation.
  • $1,698
Backorder
Size
QTY
TargetMol | Inhibitor Sale
Cudratricusxanthone A
TN5901740810-42-8
Cudratricusxanthone A has potent anti-proliferative, antioxidative, and monoamine oxidase inhibitory effects, it also possesses anti-cancer activities and provide a basis for developing effective therapeutic agents to inhibit growth and metastasis of brea
  • $2,798
Backorder
Size
QTY
TargetMol | Inhibitor Sale
Z16078526
T77621852222-94-7
Z16078526 enhances thermogenesis in mice by inducing endogenous Ucp1 expression, promoting p38 MAPK phosphorylation, and stimulating lipolysis in primary mouse brown adipocytes. Additionally, it activates thermogenic gene expression and mitochondrial activity, specifically uncoupled respiration, in these cells.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Sale
FR 167653
T11327158876-66-5
FR 167653 sulfate, an orally active and selective inhibitor of p38 MAPK, is effective in treating inflammation, trauma, and ischemia-reperfusion injury in vivo. It acts as a potent suppressor of TNF-α and IL-1β production through specific inhibition of p38 MAPK activity.
    5 days
    Inquiry